• Mary McGann, Assuntina Sacco, and Linda Barnachea.
• Mary McGann, PharmD, PGY-2 Oncology Pharmacy Resident, Department of Pharmacy, UC San Diego Health, San Diego, California, USA; Assuntina Sacco, MD, Medical Oncologist; Associate Professor of Medicine, Division of Hematology-Oncology, Moores Cancer Center, UC San Diego Health, San Diego, California, USA; Linda Barnachea, PharmD, BCOP, Clinical Pharmacist, Department of Pharmacy, UC San Diego Health, San Diego, California, USA.
• J Pain Palliat Care Pharmacother. 2021 Dec 1; 35 (4): 240-245.

AbstractAn abuse-deterrent, microsphere-in-capsule extended-release formulation of oxycodone myristate (Xtampza® ER, Collegium Pharmaceutical Inc, Canton, Massachusetts), was approved by the FDA in 2016 for the management of pain. The advantage of this formulation of oxycodone is that the microspheres can be administered via enteral tubes without compromising the long-acting formulation. This case series characterizes the experiences of five head and neck cancer patients initiated on oxycodone myristate through enteral tube administration for control of cancer-related pain. The primary outcome of patient reported subjective improvement in pain within one week occurred in all five patients. The median time to pain control was 4 days. The safety profile of oxycodone myristate was consistent with the package insert with no new findings reported. Oxycodone myristate can be an appropriate long-acting opioid analgesic option for patients requiring enteral tube administration of medications to achieve adequate cancer-related pain control.

21 keywords...

hide…